Aldeyra Therapeutics, Inc. (ALDX)
$
5.36
+0.04 (0.75%)
Key metrics
Financial statements
Free cash flow per share
-0.6666
Market cap
322.5 Million
Price to sales ratio
0
Debt to equity
0.3156
Current ratio
2.7194
Income quality
0.9280
Average inventory
0
ROE
-0.7225
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aldeyra Therapeutics, Inc. is a biotechnology company that specializes in developing and commercializing innovative treatments for immune-mediated ocular and systemic diseases. The company reported an income before tax of -$55,851,444.00 showcasing its pre-tax profitability, and it achieved a revenue of $0.00 indicating its niche market focus. Furthermore, the income before tax ratio is 0.00 reflecting the pre-tax margin. As part of its financial operations, the company incurred an interest expense of $1,926,241.00 which underscores its debt servicing obligations. Additionally, the net total of other income and expenses is $4,265,588.00 reflecting non-core financial activities. Aldeyra's lead product candidate, reproxalap, currently in Phase III clinical trials, aims to address dry eye diseases and allergic conjunctivitis. The company is also advancing ADX-629, a first-in-class orally administered RASP modulator presently in Phase II trials for psoriasis, asthma, and COVID-19, alongside ADX-2191, a dihydrofolate reductase inhibitor that is in Phase 3 for the prevention of proliferative vitreoretinopathy and Phase II for retinitis pigmentosa and primary vitreoretinal lymphoma. Additionally, Aldeyra has a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, which targets the protein chaperome for treating inflammatory diseases. The company, originally founded as Aldexa Therapeutics, Inc., rebranded to Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts. In the current market landscape, Aldeyra’s stock is affordable at $4.93 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 1,057,068.00 indicating lower market activity. With a market capitalization of $322,472,463.00 the company is classified as a small-cap player in the biotechnology field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth within the healthcare domain. As Aldeyra Therapeutics continues to develop its product pipeline, it remains committed to addressing urgent medical needs while achieving financial growth and stability.
Is Aldeyra Therapeutics, Inc. (ALDX) a good investment?
Investing in Aldeyra Therapeutics, Inc. (ALDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Aldeyra Therapeutics, Inc. (ALDX)'s stock forecast?
Analysts predict Aldeyra Therapeutics, Inc. stock to fluctuate between $1.14 (low) and $7.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aldeyra Therapeutics, Inc.'s market capitalization?
As of 2026-01-30, Aldeyra Therapeutics, Inc.'s market cap is $322,472,463, based on 60,162,773 outstanding shares.
How does Aldeyra Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aldeyra Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aldeyra Therapeutics, Inc. (ALDX) stock?
To buy Aldeyra Therapeutics, Inc. (ALDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Aldeyra Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Aldeyra Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.94 | Growth: 46.88%.
Where can I find Aldeyra Therapeutics, Inc.'s investor relations reports?
Visit https://www.aldeyra.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aldeyra Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aldeyra Therapeutics, Inc. stock?
All-time high: $11.97 (2023-06-15) | All-time low: $1.14 (2025-04-03).
What are the key trends affecting Aldeyra Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Aldeyra's Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a procedural PDUFA extension. Reproxalap's Chamber Phase 3 trial met symptom endpoints with rapid, durable relief. However, the main risk is that the field trial missed the primary symptom endpoint while showing supportive signals.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Fol.
seekingalpha.com
Aldeyra Therapeutics, Inc. ( ALDX ) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye November 13, 2025 8:00 AM EST Company Participants Laura Nichols - Operations Manager Todd Brady - CEO, President & Director Adam Lazorchak Conference Call Participants Thomas Shrader - BTIG, LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Clara Dong Yale Jen Presentation Operator Hello, and welcome, everyone, to the Aldeyra Therapeutics 2025 Research and Development Update Webcast. My name is Becky, and I'll be your operator today.
zacks.com
Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
seekingalpha.com
Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.
globenewswire.com
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
See all news
